PCSK9s' 'Very Low' LDL-C Debate Could Be Symptom Of Dosing Differences
Executive Summary
FDA advisors ponder effects of extremely reduced LDL-cholesterol levels as Amgen and Sanofi/Regeneron offer different interpretations playing to the strengths of Repatha and Praluent.